Health Biotech Limited
Health Biotech Limited
Sector 34-A, Chandigarh
SEND SMS
SEND EMAIL

Anticancer Injectables

Offering you a complete choice of products which include cisplatin injection, cyclophosamide injection, oxaliplatin for injection, paclitaxel injection, doxorubicin injection and etoposide injection.

Cisplatin Injection

Cisplatin Injection
  • Cisplatin Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
Medicine TypeAllopathic
Usage/ApplicationCommercial
Product TypeFinished Product

Cisplatin is used to treat various types of cancer. It is a chemotherapy drug that contains platinum. It is used alone or in combination with other medications to slow or stop cancer cell growth.

Each vial contains:- Cisplatin- 10mg and 50mg

Request
Callback
Yes! I am interested

Cyclophosamide Injection

Cyclophosamide Injection
  • Cyclophosamide Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
TypeAllopathic

Category: Antineoplastic
Composition- : Each vial contains Cyclophosphamide eq. to Cyclophosphamide (anhydrous) 200mg ,500mg,1000mg .
It is an antineoplastic and immuno modulating agent. It is bio-transformed in liver to active alkylated metabolite. These metabolites interfere with growth of susceptible rapidly multiplying malignant cells by cross-linking of tumour cell-DNA.

Specification-cyclophosphamide for injection, is a sterile white powder containing cyclophosphamide monohydrate. Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. Cyclophosphamide is a white crystalline powder with the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1. Cyclophosphamide is soluble in water, saline, or ethanol .
pH------------ 3.0 to 9.0
Indication :Cyclophosphamide although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment:
• Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma.
• Multiple myeloma.
• Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocyticleukemia, acute lymphoblastic (stem-cell) leukemia in children cyclophosphamide given during remission is effective in prolonging its duration)..
• Carcinoma of the breast.
Dosage :-Adults and Children:
When used as the only oncolytic drug therapy, the initial course of cyclophosphamide for patients with no hematologic deficiency usually consists of 40 to 50 mg/kg given intravenously in divided doses over a period of 2 to 5 days. Other intravenous regimens include 10 to 15 mg/kg given every 7 to 10 days or 3 to 5 mg/kg twice weekly.
Contraindications:-In patients with history of hypersensitivity to the drug, pregnancy, location.
Precautions:-Special attention to the possible development of toxicity should be exercised in patients being treated with cyclophosphamide if any of the following conditions are present.
• Leukopenia
• Thrombocytopenia
• Tumor cell infiltration of bone marrow
• Previous X-ray therapy
Previous therapy with other cytotoxic agents
Drug interaction:The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.
Since cyclophosphamide has been reported to be more toxic in adrenalectomized dogs, adjustment of the doses of both replacement steroids and cyclophosphamide may be necessary for the adrenalectomized patient.
Adverse Effect-:Sterility in both sexes may occur, amenorrhoea, haemorrhagic cystitis, fibrosis of bladder, nausea, vomitting, anorexia, alopecia, skin rash, pigmentation, leucopenia, thrombocytopenia, intestinal pulmonary fibrosis, anaphylactic reactions.
Request
Callback
Yes! I am interested

Oxaliplatin for Injection

Oxaliplatin for Injection
  • Oxaliplatin for Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size100 mg
Product TypeFinished Product
UsageCommercial, Clinical, Hospital
Packaging TypeBox
Medicine TypeAllopathic
Form of MedicineInjection
BrandCure-X 100

Category: Anticancer
Each vial contains:- Oxaliplatin  2 mg per ml
Pack Size:-25ml , 50 ml

Oxaliplatin is a neoplastic drug used in metastatic colorectal cancer where fluropyrimidines therapy or alone chemotherapy have failed, also used along with fluropyrimidines.

Composition :Each vial contains: 
Oxaliplatin -------------------25mg, 50mg, 100mg 
Water for injection -----------q.s.
Indications :oxaliplatin used in combination with infusional 5-fluorouracil/leucovorin, is indicated for:
• adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
treatment of advanced colorectal cancer.
.
Contraindications :Oxaliplatin should not be administered to patients with a history of known allergy to oxaliplatin or other platinum compounds .

Adverse Effects :Serious adverse reactions including anaphylaxis and allergic reactions, neuropathy,pulmonary toxicities and hepatotoxicities can occur..
Dosage :oxaliplatin 85 mg/m² intravenous infusion in 250-500 mL 5% Dextrose injection, USP and leucovorin 200 mg/m² intravenous infusion in 5% Dextrose Injection, USP both given over 120 minutes at the same time in separate bags using a Y-line, followed by 5-fluorouracil 400 mg/m² intravenous bolus given over 2-4 minutes, followed by 5-fluorouracil 600 mg/m² intravenous infusion in 500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous infusion.
Day 2: Leucovorin 200 mg/m² intravenous infusion over 120 minutes, followed by 5-fluorouracil 400 mg/m² intravenous bolus given over 2-4 minutes, followed by 5-fluorouracil 600 mg/m² intravenous infusion in 500 mL 5% Dextrose Injection, USP (recommended) as a 22-hour continuous infusion.
Pharmacological action :Oxaliplatin is a neoplastic drug used in metastatic colorectal cancer where fluropyrimidines therapy or alone chemotherapy have failed, also used along with fluropyrimidines. 
Precautions : Oxaliplatin may rarely cause a severe (possibly fatal) allergic reaction within minutes after a dose. Tell your doctor immediately if you develop any signs of an allergic reaction (e.g., rash, itching, swelling, trouble breathing, dizziness)..
Drug interaction:No pharmacokinetic interaction between 85 mg/m² of Oxaliplatin and infusional 5-fluorouracil has been observed in patients treated every 2 weeks, but increases of 5-fluorouracil plasma concentrations by approximately 20% have been observed with doses of 130 mg/m² of Oxaliplatin administered every 3 weeks. In vitro, platinum was not displaced from plasma proteins by the following medications: erythromycin, salicylate, sodium valproate, granisetron, and paclitaxel. In vitro, oxaliplatin is not metabolized by, nor does it inhibit, human cytochrome P450 isoenzymes. No P450-mediated drug-drug interactions are therefore anticipated in patients..
Precautions:Oxaliplatin may rarely cause a severe (possibly fatal) allergic reaction within minutes after a dose.
Request
Callback
Yes! I am interested

Paclitaxel Injection

Paclitaxel Injection
  • Paclitaxel Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Medicine TypeAllopathic
Form of MedicineInjection
UsageCommercial

Paclitaxel is used to treat various types of cancer. It is a cancer chemotherapy drug that works by slowing or stopping cancer cell growth.

 

Paclitexal 30/100/260 Mg Inj

Request
Callback
Yes! I am interested

Doxorubicin Injection

Doxorubicin Injection
  • Doxorubicin Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
Product TypeFinished Product
Medicine TypeAllopathic
Usage/ApplicationCommercial
TypeAllopathic

Category: Anti neo-plastic
Each vial contains:- Doxorubicin….. 10mg and 50mg
It is a antitumour antibiotic and finds a useful application in acute leukemia & in many solid tumours. Doxorubicin is capable of cusing breaks in DNA strands and have mutagenic and carcinogenic potential. Maximum action is exerted at S phase, but toxicity is usually exhibited in G2 phase.

Composition :Each vial contains:
DoxorubicinHydrochloride………….10mg, 50mg, 100mg
Lactose Monohydrate ………………..50mg, 200mg, 500mg
Indications :Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblasticleukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types.
Contraindications :In patients with history of hypersensitivity to the drug, pregnancy, location.
Pharmacological action:: It is a antitumour antibiotic and finds a useful application in acute leukemia & in many solid tumours. Doxorubicin is capable of cusing breaks in DNA strands and have mutagenic and carcinogenic potential. Maximum action is exerted at S phase, but toxicity is usually exhibited in G2 phase
Adverse Effects :: Cardiotoxicity, alopecia, Bone marrow depression, alopecia, cardiomyopathy, stomatitis, vomiting and local tissue damage.
Dosage :1.2-2.4 mg/kg body wt or 60-75 mg/sq metre of body surface given as a single dose every 3 week by slow i.v. inj. Doxorubicin has been used concurrently with other approved chemotherapeutic agents. Evidence is available that in some types of neoplastic disease combination chemotherapy is superior to single agents. The benefits and risks of such therapy continue to be elucidated. When used in combination with other chemotherapy drugs, the most commonly used dosage of doxorubicin is 40 to 60 mg/m2 given as a single intravenous injection every 21 to 28 days.
Drug interaction:Doxorubicin is extensively metabolized by the liver. Changes in hepatic function induced by concomitant therapies may affect doxorubicin metabolism, pharmacokinetics, therapeutic efficacy, and/or toxicity. Toxicities associated with doxorubicin, especially hematologic and gastrointestinal events, may be increased when doxorubicin is used in combination with other cytotoxic drugs.
Precautions:ECG changes, arrhythmias, hypotension, or be delayed congestive heart failure.Doxorubicin may cause heart problems, including possibly fatal heart failure. Heart problems may occur durin doxorubicin therapy or months to years after receiving this medication

Request
Callback
Yes! I am interested

Etoposide Injection

Etoposide Injection
  • Etoposide Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
Medicine TypeAllopathic

Composition :- Each ml contains Etoposide 20mg/ml

Indication :Small cell lung cancer. Malignant lymphomas. Acute leukaemias, Testicular tumours. Bladder cancer & trophoblastic diseases.
Dosage :-In small cell lung cancer, the recommended dose of Etoposide Capsules is two times the IV dose rounded to the nearest 50 mg (i.e., two times 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days). Chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity.
Contra Indications :-Hypersensitivity, severe liver dysfunction.
Special Precautions :-Renal disease, infections, avoid contact with the skin, mucosa and eye and should not be used in pregnancy, nursing mother and elderly.
Pharmacological action:Etoposide has been shown to cause metaphase arrest in chick fibroblasts. Its main effect, however, appears to be at the G2 portion of the cell cycle in mammalian cells. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3-10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA topoisomerase II or the formation of free radicals.
Pregnancy :-Should not be used..
Lactation :-Should not be used.
Elderly :-Should not be used.
Adverse effect: -: Myelosuppression, nausea and vomiting, Anaphylactic-like reactions characterized by chills, fever, tachycardia, bronchospasm, dyspnea, and hypotension, Rash, urticaria, and/or pruritus, Alopecia, abdominal pain, aftertaste, constipation, dysphagia, asthenia, fatigue, malaise, somnolence, transient cortical blindness, optic neuritis, interstitial pneumonitis/pulmonary fibrosis, fever, seizure (occasionally associated with allergic reactions), Stevens-Johnson syndrome, and toxic epidermal necrolysis, pigmentation. .
Storage: -Etoposide Capsules must be stored under refrigeration 2° - 8° C (36° - 46° F). The capsules are stable for 24 months under such refrigeration conditions.
Drug Interactions :-Synergism with other cytotoxic drugs.
Purity :Not less than 99%.
Request
Callback
Yes! I am interested

Docetaxel Injection

Docetaxel Injection
  • Docetaxel Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
Medicine TypeAllopathic

Docetaxel Injection

 


Each vial contains:- Docetaxel 20mg, 80 mg and 120mg
It is an anti-neoplastic agent.

 

Composition :

20mg/0.5 ml, 80mg/2ml, & 120mg/3ml

Indication :

Cancer : Breast, non-small cell lung cancer, prostate, bladder, stomach, Esophagus, overy,head and neck.

Dosage :-

Administered parenterally. The dose should be individualized depending on the size of the patient and whether or not other medicines are also being taken. Adults: 60 to 100 mg /1.73 ml intravenously.

Contra Indications :-

Hypersensitivity , alcohol abuse or history of, chickenpox, herps zoster, fluid in lungs, infection , liver disease.

Special Precautions :-

Immunization specifically persons living in the patients household should not take oral polio vaccine.

Paediatrics :

Only limited studies are done.

Pregnancy :-

Contraindicated.

Lactation :-

Generally not recommended.

Elderly :-

Use with caution.

Side Effects :-

Mild nausea and vomiting, headache, palpitation, tightness in chest, chest pain , heart problem , hypotension, or hypertension , congestion ,diarrhoea, arthalgia, myalgia, puffiness of face, stomatitis , oedema, weight gain , tingling and numbness of face ,stomatitis, extremities , black- tarry stools , hematuria, difficult and painful alopecia , induration at the site of injection .

Drug Interactions 

Amphotericin- B , ketoconazole , antithyroid agents ,erythromycin troleandomycin , colchicine, flucytosine, ganciclovir , zidovudine, interferon, cyclophosphamide, orphenadine, midazolam, radiation, therapy.

Request
Callback
Yes! I am interested

Gemcitabine Injection

Gemcitabine Injection
  • Gemcitabine Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

UsageHospital
Form of MedicineInjection

Gemcitabine Injection

Category: Anti neo-plastic
Each vial contains:- Gemcitabine Hydrochloride equivalent to Gemcitabine 200mg , 1000mg, 1400mg Mannitol 200 mg, 1000mg, 1400mg

Composition :

Each lyophilized vial contains:
Gemcitabine Hydrochloride
equivalent to Gemcitabine 200mg , 1000mg, 1400mg
Mannitol .200 mg, 1000mg, 1400mg

Indication :

Gemcitabine hcl in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer.
Gemcitabine hcl in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer.
Gemcitabine hcl is indicated in combination with cisplatin for the first-line treatment of patients with non-small cell lung cancer.
Gemcitabine hcl is indicated as first-line treatment for patients with adenocarcinoma of the pancreas. Gemcitabine hcl is indicated for patients previously treated with 5-FU

Dosage :-

Adult : Administered i.v. at a dose of 1000 mg/m² over 30 minutes, once weekly for upto 7 weeks or if toxicity calls for reducing or holding a dose. Followed by a week of rest from treatment subsequent cycles consist of infusions one weekly for three weeks out of every 4 weeks.

Contra Indications :-

Gemcitabine hcl is contraindicated in those patients with a known hypersensitivity to the drug.

Adverse effect :-

Most adverse reactions are reversible and do not need to result in discontinuation, although doses may need to be withheld or reduced. Myelosuppression, Nausea and vomiting, mild proteinuria and hematuria, fever, rash, dyspnea, edema, infection, alopecia, bronchospasm

Storage:

Gemcitabine hcl are stable when stored at controlled room temperature 20° to 25°C (68° to 77°F) and that allows for excursions between 15° and 30°C (59° and 86°F)

Pharmacological action: B>

Gemcitabine exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and also blocking the progression of cells through the Gl/S-phase boundary. Gemcitabine is metabolized intracellular by nucleoside kinases to the active diphosphate and triphosphate nucleosides.

Specification: -

Gemcitabine for injection is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HC1 is 2'-deoxy-2',2'-difluorocytidine monohydrochloride (β-isomer). The empirical formula for Gemcitabine HC1 is C9H11F2N3O4 HCI It has a molecular weight of 299.66. Gemcitabine HC1 is a white to off-white solid. It is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents

Drug Interactions :-

No specific drug interaction studies have been conducted.

Request
Callback
Yes! I am interested

L- Asparaginase Injection

L- Asparaginase Injection
  • L- Asparaginase Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
TypeAllopathic

Category: Antineoplastic
Composition:- Each vial contains L-Asparaginase 5000IU/10000 IU
The rationale behind asparaginase is that it takes advantage of the fact that ALL leukemic cells are unable to synthesize the non-essential amino acid asparagine, whereas normal cells are able to make their own asparagine; thus leukemic cells require high amount of asparagine. These leukemic cells depend on circulating asparagine. Asparaginase, however, catalyzes the conversion of L-asparagine to aspartic acid and ammonia. This deprives the leukemic cell of circulating asparagine.

Specification-Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid. It is used for the treatment of acute lymphoblastic leukemia (ALL)[1] and is also used in some mast cell tumor protocols. [2] Unlike other chemotherapy agents, it can be given as an intramuscular, subcutaneous, or intravenous injection without fear of tissue irritation.
Indication :Acute leukaemia, Malignant lymphoma.
Dosage :-50-200 k.u/kg body wt. daily or every alternate day by I.V infusion.
Contraindications:-• Hypersensitivity or previous serious allergic reaction (such as generalized urticaria, bronchospasm, laryngeal edema, hypotension) to drug.
• Pancreatitis or history of pancreatitis.
• Previous hemorrhagic events related to L-asparaginase therapy
Precautions:-• renal or hepatic disease, CNS disorders.
• concurrent use of hepatotoxic agents, anticoagulants, or other nonsteroidal anti-inflammatory drugs (NSAIDs)
• pregnant or breastfeeding patients.
Drug interaction:and increases the toxicity, diminishes or abolishes the effect of methotrexate on malignant cells.
Adverse Effect-:The main side effect is an allergic or hypersensitivity reaction; anaphylaxis is a possibility.[1] Asparaginase has also been associated with pancreatitis. Additionally, it can also be associated with a coagulopathy as it decreases protein synthesis, including synthesis of coagulation factors (eg progressive isolated decrease of fibrinogen) and anticoagulant factor (generally antithrombin III; sometimes protein C & S as well), leading to bleeding or thrombotic events such as stroke.
Storage:Store between +2°C and +8°C.
Purity:-100 %
Request
Callback
Yes! I am interested

Ifosfamide Injection

Ifosfamide Injection
  • Ifosfamide Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial, Clinical, Hospital
TypeAllopathic

Category: Anti-neoplastic
Composition:- Each lyophilized vial contains Ifosfamide USP 1gm/2 gm
Ifosfamide is an alkylating agent.Following activation in the liver, ifosfamide interfare with Dna through formation of phosphotriesters and DNA-DNA crosslinks, thereby inhibiting protein synthesis and DNA synthesis.

Specification-pH range – : 4.0 to 7.0
Description-: Ifosfamide belongs to the group of medicines called alkylating agents. It is used to treat cancer of the testicles as well as some other kinds of cancer. Another medicine, called mesna, is usually given along with ifosfamide to prevent bladder problems that can be caused by ifosfamide.
Indication :Ifosfamide , used in combination with certain other approved antineoplastic agents, is indicated for third line chemotherapy of germ cell testicular cancer. It should be used in combination with a prophylactic agent for hemorrhagic cystitis.
Dosage :-Ifosfamide should be administered intravenously at a dose of 1.2 g/m² per day for 5 consecutive days. Treatment is repeated every 3 weeks or after recovery from hematologic toxicity.
Contra Indications:-Continued use of ifosfamide is contraindicated in patients with severely depressed bone marrow function ifosfamide is also contraindicated in patients who have demonstrated a previous hypersensitivity to it.
Precautions:-Ifosfamide should be discontinued if neurologic symptoms of somnolence, irritability, anxiety, confusion, hallucinations, or coma are observed. Use with caution in patients with renal or hepatic impairment.
Drug interaction:The concurrent use of ifosfamide may enhance the anticoagulant effect of and thus raise the risk of haemohorrage .
Side Effect-:Severe nausea, vomiting, Dizziness, Fatigue, Bone marrow depression and Allergic reaction like difficult breathing and swelling of face and lips.
Storage:Store at 2-8ºC (35-46ºF) and protect from light.
Request
Callback
Yes! I am interested

Disodium Pamidronate Injection

Disodium Pamidronate Injection
  • Disodium Pamidronate Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Product TypeFinished Product
UsageCommercial
Dosage FormInjection
Form of MedicineInjection

Pamidronate is used to treat high blood calcium levels and certain bone problems (bone metastases/lesions) that may occur with some types of cancer. It is also used to treat a certain type of bone disease (Paget's disease) that causes abnormal and weak bones. Pamidronate belongs to a class of drugs known as bisphosphonates. It works by slowing the release of calcium from bones to lower blood calcium levels, reducing the risk of broken bones (fractures) and reducing bone pain.

Pamidronate 30/60/90 Mg Inj

 

Request
Callback
Yes! I am interested

Zoledronic Acid Injection

Zoledronic Acid Injection
  • Zoledronic Acid Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

UsageCommercial
Form of MedicineInjection

Category: Anti-neoplastic
Each vial contains:- Zoledronic acid 4mg

Zoledronic acid is a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronic acid is designated chemically as (l-Hydroxy-2-imidazol-l-yl-phosphonoethyl) phosphonic acid monohydrate. Zoledronic acid is a white crystalline powder. Its molecular formula is C5H10N2O7P2•H2O and its molar mass is 290.1g/Mol. Zoledronic acid is highly soluble in 0.1N sodium hydroxide solution, sparingly soluble in water and 0.1N hydrochloric acid, and practically insoluble in organic solvents. The pH of a 0.7% solution of zoledronic acid in water is approximately 2.0.

Composition :Each vial contains:
Zoledronic acid monohydrate 4.264mg
eq to Zoledronic acid……………..4mg
Indication :Zoledronic acid is indicated for the treatment of hypercalcemia, multiple myeloma, bone metastases, osteoporosis in men and women.
Dosage :-Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. The maximum recommended dose of Zoledronic acid in hypercalcemia of malignancy (albumin-corrected serum calcium greater than or equal to 12 mg/dL [3.0 mmol/L]) is 4 mg. The 4-mg dose must be given as a single-dose intravenous infusion over no less than 15 minutes. Patients who receive Zoledronic acid should have serum creatinine assessed prior to each treatment.
Contra Indications:-Hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported.
Precautions:-Patients with hypercalcemia of malignancy must be adequately rehydrated prior to administration of Zoledronic acid, treatment is not recommended in patients with bone metastases with severe renal impairment and in hepatic impairement.
Pharmacological Action:The principal pharmacological action of Zoledronic acid is inhibition of bone resorption. In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid also blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acid inhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factors released by tumors.
Drug interaction:In-vitro studies indicate that Zoledronic acid is approximately 22% bound to plasma proteins. In-vitro studies also indicate that Zoledronic acid does not inhibit microtonal CYP450 enzymes. In-vivo studies showed that Zoledronic acid is not metabolized, and is excreted into the urine as the intact drug.
Adverse effect:Administration of Zoledronic acid 4 mg given as a 5-minute intravenous infusion has been shown to result in an increased risk of renal toxicity The most frequently observed adverse events were fever, nausea, constipation, anemia, and dyspnea. rash, pruritus.
Storage:Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).

Request
Callback
Yes! I am interested

Bleomycin Injection

Bleomycin Injection
  • Bleomycin Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
Medicine TypeAllopathic

Bleomycin Injection

Category: anti-neoplastic

Each vial contains:-Bleomycin sulphate 15 units, 30 units
Bleomycin sulfate for injection is a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of streptomyces verticillus. It is freely soluble in water. Between 4. 5 to 6. 0

 

Pharmacological Action :

Bleomycin is a mixture of cytotoxic glycopeptide antibiotics. It inhibits DNA synthesis. When administered intrapleurally, bleomycin acts as a sclerosing agent.

Precautions:

It is recommended that Bleomycin be administered under the supervision of a qualified health care provider experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Before using Bleomycin Sulfate for injection medication, tell your doctor or pharmacist your medical history, especially: immune system problems (e.g., chemotherapy, bone marrow problems), kidney disease, liver disease, lung problems.

Indications:

Bleomycin Sulfate Injection should be considered a Palliative Treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved
chemotherapeutic agents: Squamous Cell Carcinoma in Head and neck including mouth, tongue, tonsil, Nasopharynx, Oropharynx, Sinus, palate, Lip, Buccal Mucosa, Gingivae , Epiglottis, skin, Larynx, Cervix, and Vulva. Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Contraindications :

Bleomycin Sulfate injection is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to it.

Adverse Effects :

Pneumonitis progressing to pulmonary anaphylactoid reactions, erythema, rash, striae, vesiculation, hyperpigmentation, rarely myocardial infarction, cerebrovascular accident, haemolytic uraemia syndrome, cerebral arthritis.
Local reactions : Pain, pruritus, hyperpigmentation, scarring, suppuration scaling.

Dosage :

Bleomycin Sulfate injection may be given by the Intramuscular, intravenous, subcutaneous, or Intrapleural routes. Squamous cell carcinoma, non-Hodgkin's lymphoma, testicular carcinoma- 0.25 to 0.50 units/kg (10 to 20 units/m) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly.
Hodgkin's disease :- 0.25 to 0.50 units/kg (10 to 20 units/m) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly.
Note: When Bleomycin sulfate injection is used in combination with other antineoplastic agents, pulmonary toxicities may occur at lower doses.
Malignant Pleural Effusion - 60 units administered as a single dose Bolus Intrapleural Injection.
Intramuscular or Subcutaneous: Bleomycin Sulfate injection 15 units vial should be reconstituted with 1 to 5 ml of Sterile Water for Injection, Sodium Chloride for Injection 0.9% or Sterile Bacteriostatic Water for Injection. Bleomycin Sulfate injection 30 units vial should be reconstituted with 2 to 10 ml of the above diluents.
Intravenous: The contents of the 15 units or 30 units vial should be dissolved in 5 ml or 10 ml, respectively, of Sodium Chloride for Injection, 0.9% and administered slowly over a period of 10 minutes.

Storage :

2-8oC


Request
Callback
Yes! I am interested

Mesna Injection

Mesna Injection
  • Mesna Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
Medicine TypeAllopathic
TypeAllopathic

Category: Chemoprotectant/Cytoprotective Agent/ Antidotes
Composition- : Each ml contains: Mesna 100mg Water for Injection q.s.
Mesna is used to reduce the incidence of ifosfamide-induced hemorrhagic cystitis. Mesna disulfide is reduced to the free thiol compound, mesna, which reacts chemically with the urotoxic ifosfamide metabolites, resulting in their detoxification.

Specification-pH range – : 4.5 to 7.0
Mesna Injection is a detoxing agent to inhibit the hemorrhagic cystitis induced by ifosfamide. It is a sterile, nonpyrogenic, aqueous solution of clear and colorless to light pink appearance in clear glass multidose vials for intravenous administration. It is used to prevent bleeding from the bladder during ifosfamide or cyclophosphamide chemotherapy.
Indication :Prevention of toxicity to the urinary passage caused by cyclophosphamide or Trofosfamide.
Dosage :-I.V. 20% of the dose of anti-neoplastic on weight basis, over 15-30 minutes at 4 hours interval
Contraindications:-Hypersensitivity.
Precautions:-Tell your doctor and pharmacist if you are allergic to mesna or any other drugs.
Tell your doctor and pharmacist what prescription and nonprescription medications you are taking, including vitamins.
Tell your doctor if you have or have ever had liver or kidney disease.
Tell your doctor if you are pregnant or breast-feeding. You should not plan to have children while receiving chemotherapy or for a while after treatments. (Talk to your doctor for further details.) Use a reliable method of birth control to prevent pregnancy.
Do not have any vaccinations (e.g., measles or flu shots) without talking to your doctor.
Drug interaction:Mercaptopurine, Cyclophosphamide, , Digoxin.
Adverse Effect-:G.I. Disturbance, headache, skin rash, tachycardia, hypotension
Storage:After preparation, this medication is stable for 24 hours at 77 degrees F (25 degrees C). Before preparation, store the vials at room temperature between 59 and 86 degrees F (15-30 degrees )
Purity:-99.5%
Request
Callback
Yes! I am interested

Dacarbazine Injection

Dacarbazine Injection
  • Dacarbazine Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

UsageCommercial
Form of MedicineInjection

Category: Anti-neoplastic
Each lyophilized vial contains:- Dacarbazine USP 100mg/ 200 mg/ 500mg
It is an unidarole derivative. Exact machanism of action is not known. Three hypothesis have been proposed. • Inhibition of DNA synthesis by acting as purine analogue. • Action as an alkylating agent. • Interaction with - SH group. pH ranges from 3.0 to 4

Indication :Dacarbazine for injection is indicated in the treatment of metastatic malignant melanoma. In addition, dacarbazine for injection is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents.
Dosage :-Malignant melanoma : 2-4.5 mg/kg/day for 10 days may be repeated at 4 weeks intervel or 250 mg/ml of body surface area (BSA)/day for 5 days repeated after 3 weeks. Hodgkin's disease : 150mg/m² to be repeated every 15 days.
Contra Indications:-Dacarbazine for injection is contraindicated in patients who have demonstrated a hypersensitivity to it in the past.
Precautions:-Breast-feeding is usually stopped while using anticancer drugs. Dacarbazine should be used only when clearly needed during pregnancy.
Drug interaction:Impairs immune response to vaccines; possible infection after admin of live vaccines. Effect increased by CYP1A2 inhibitors e.g. amiodarone, ciprofloxacin, fluvoxamine, ketoconazole, lomefloxacin, ofloxacin and Effect decreased by CYP1A2 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital and rifampicin.
Adverse effects:Haemopoietic depression invading mainly leucocytes and platelets anaphylactoid reaction, anorexia, nausea, vomiting, diarrhoea, influneza like syndrome, alopecia, facial flushing, paresthesia, ash liver function and renal function abnormalities
Storage:Store in a refrigerator 2°C to 8°C (36°F to 46°F). dacarbazine Use within 8 hours of reconstitution. Protect from light

Request
Callback
Yes! I am interested

Topotecan Injection

Topotecan Injection
  • Topotecan Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
TypeAllopathic

Category: Antineoplastic
Composition- : Each vial contains: Topotecan HCl equivalent to Topotecan 2.5mg/2.5ml, 4mg/4ml.
Topotecan is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death). Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream ( 1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor.

Specification-Light Greenish color powder filled in glass vials.
pH------------ 2.5 to 4.5
Indication :Metastatic carcinoma of the ovary after failure of initial or subsequent chemo therapy. Small cell lung cancer disease after failure of first line chemotherapy
Dosage :-The recommended starting dose is 1.5mg/m2 body surface area by IV infusion over 30 minutes daily for 5 consecutive days In absence of tumor progression, a minimum of four courses are recommended, as tumour response may be delayed.
Contraindications:-Severe hypersensitivity reactions (e.g., anaphylactoid reactions)
Pregnant or Breastfeeding,
Severe bone marrow depression.
Precautions:-Bone Marrow Suppression, Thrombocytopenia, Diarrhea, Interstitial Lung Disease, Pregnancy Neutropenia, Thrombocytopenia, Anemia.
Drug interaction:Cyclosporine A (inhibitor of ABCB1, ABCC1 [MRP-1], and CYP3A4) with hycamtin capsules increased topotecan exposure to 2- to 3-fold of control. The pharmacokinetics of topotecan were generally unchanged when coadministered with ranitidine.
Adverse Effect-:Bone marrow suppression. Primarily neutropenia, thrombocytopenic anaemia, abdominal discomfort.
Storage:Store between 2-80C
Purity:-Not less than 99.5%.

Request
Callback
Yes! I am interested

Epirubicin Injection

Epirubicin Injection
  • Epirubicin Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
TypeAllopathic

Category: Anti-neoplastic
Each vial contains:- Epirubicin - 10mg , 50mg and 100mg

It is a new anthracycline with antiblastic activity. The mechanism of action of it is related to its ability to bind to DNA. Cell culture studies have shown rapid cell penetration, localization in the nucleus and inhibition of nucleic acid synthesis and mitosis.

Composition :Each lyophilized Vial contains:
Epirubicin Hydrochloride – 10mg, 50mg, 100mg
Indication :It is used in the Adjuvant Treatment of Breast Cancer
Specification: :Epirubicin Hydrochloride Injection is supplied as a sterile, clear, red solution and is available in polypropylene vials containing 50 and 200 mg of Epirubicin Hydrochloride as a preservative-free, ready-to-use solution. pH Between 4.0 to 5.5
Dosage :-Administer Epirubicin Injection by intravenous infusion. Give Epirubicin in repeated 3- to 4-week cycles. The total dose of Epirubicin may be given on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle.
Patients administered the 120-mg/m² regimen of Epirubicin should receive prophylactic therapy. Administering a lower starting dose (75-90 mg/m²) for heavily pretreated patients, patients with pre-existing bone marrow depression, or in the presence of neoplastic bone marrow infiltration
Contra Indications:-Patients should not be treated with Epirubicin Injection if they have any of the following conditions:Severe myocardial insufficiency, recent myocardial infarction or severe arrhythmias
Special Precautions:-Administer Epirubicin Injection only under the supervision of qualified physicians experienced in the use of cytotoxic therapy. Before beginning treatment with Epirubicin, patients should recover from acute toxicities (such as Stomatitis, neutropenia, thrombocytopenia, and generalized infections) of prior cytotoxic treatment. Also, precede initial treatment with Epirubicin by a careful baseline assessment of blood counts; serum levels of total Bilirubin, AST, and Creatinine; and cardiac function as measured by left ventricular ejection function (LVEF). Carefully monitor patients during treatment for possible clinical complications due to Myelosuppression.
Pharmacological Action:
Epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis.Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription
Purity :Not less than 99%.
Request
Callback
Yes! I am interested

Mitoxantrone Injection

Mitoxantrone Injection
  • Mitoxantrone Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
TypeAllopathic

It is a synthetic antineoplastic anthracenedione for intravenous use. Although its mechanism of action is not fully elucidated, it is a DNA - reactive agent. It has a cytocidal effect on with proliferating and non proliferating cultured small cells suggesting lock of cell cycle specifically.
Composition :Each ml contains:
Mitoxantrone ------------------------2 mg
Indications :It is used in the treatment of metastatic breast cancer and of non-Hodgkin’s lymphomas, alone or with other agents. It may also be given to treat adult acute myeloid leukemia. Mitoxantrone has also been used in patients with hormone-refractory prostate cancer, liver cancer, and ovarian cancer. In addition, mitoxantrone is used in the management of secondary progressive or relapsing multiple sclerosis, to reduce neurological disability or the frequency of relapses.

.
Contraindications :Mitoxantrone for injection is contraindicated in patients who have demonstrated prior hypersensitivity to it.

Adverse Effects :Serious adverse reactions including anaphylaxis and allergic reactions, neuropathy,pulmonary toxicities and hepatotoxicities can occur..
Dosage :In the treatment of breast cancer, prostate cancer, liver cancer, and lymphomas, a dose equivalent to mitoxantrone 14 mg/m2 is given initially and then repeated every 3 weeks. It is diluted to at least 50 ml in sodium
chloride 0.9% or glucose 5% and injected over at least 3 minutes into a freely-running intravenous infusion of
either. Subsequent doses may be adjusted according to the degree of Myelosuppression produced. Initial dosage
may need to be reduced to 12 mg/m2 in debilitated patients or those who have had previous Hemotherapy.
Precautions:Special Populations in Carcinogenesis, Mutagenesis, Impairment of Fertility, Hepatic Impairment, Pregnancy, Nursing Mothers, Pediatric Use, Geriatric Use, Multiple Sclerosis, Hormone-Refractory Prostate Cancer, Acute Nonlymphocytic Leukemia.
Storage2-8°c
.

Request
Callback
Yes! I am interested

Daunorubicin Injection

Daunorubicin Injection
  • Daunorubicin Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
Product TypeFinished Product

It is an anthracycline cytotoxic produced by a strain of streptomyces peucetius. It inhibits the synthesis of nucleic acids and effects on DNA & particularly rapid and marked.

Composition :20mg
Indications :Remission indication in non lymphocytic leukemias, acute erythroid, leukemia, acute monocytic, leukemia, acute myelogenous leukemia, acute Lymphoblastic leukemia in children and adults.
Contraindications :Pre- existing drug induced bone marrow supression, pre-existing heart disease, pregnancy.
Safety Profile :Cardiac, renal & hepatic functions adn serum uric levels should be evaluated prior to treatment. Completed blood count should be frequently monitored during the therapy extravasation at the site of injections may causes severe local tissue necrosis.
Adverse Effects :Myelosuppression, myocardial toxicity, infants and children's are more susceptible to congestive heart failure (CHF), reversible alopecia gastrointestinal toxicity, acute nausea, vomiting, rare anaphylactoid reactions, hyperuricaemia, transient red urine.
A special preparation as daunorubicin citrate liposome contain an equal amount of citrate encapsulated in lipid vesicles, formulated to maximize the selectivity of the drug for soiled tumors in sites.
Drug Interactions :1st line drug for advanced HIV associated keposi's saecoma.
Dosage :Acute nonlymphocytic leukemia: Less than 60 years age -45 mg/m²/day i.v on days 1,2,3 on first course and on day 1&2 on subsequent course with cytosine.
Acute Lymphocytic leukemia (All): Chlidren 25 mh/ m² i.v on day every week with prednisolone and vincristine.In < 2yrs of age: mg/kg dose in same manner Adult: 45 mg/m²per day i.v on drug 1,2,3 with vincristine., prednisolone and L-asparaginase.
In < 2yrs of age: mg/kg dose in same manner Adult: 45 mg/m²per day i.v on drug 1,2,3 with vincristine., prednisolone and L-asparaginase.
Purity :Not less than 99%.
Request
Callback
Yes! I am interested

Cytosine Arabinoside Injection

Cytosine Arabinoside Injection
  • Cytosine Arabinoside Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

UsageHospital

It is phosphorylated in the body to corresponding nucleotide, which inhibits DNA repair. Cytorabine is cell cycle specific and acts primarly during S phase. Its main use is to induce remission in acute leukemia.

Composition :100mg/1ml, 500mg/5ml, 1000mg/10ml
Indications :Acute leukemias, lymphosarcomas.
Dosage:3-6 mg/Kg body wt. i.v daily in 2 divided doses for 5-10 days.
Conraindications:Hypersensitivity, Pregnancy.
Special Precautions :Hepatic impairment.
Paediatrics : Indicated in certain leukemia, under strict supervision.
Pregnancy : Safety not established
Lactation : Safety not established
Elderly : Use with caution
Side- Effect :Bone marrow suppression. G.I.T disturbances.
Drug Interaction :Potentiates bone marrow depression with radiotheraphy and other myelotoxic drugs. Reduces plasma concentration of digoxin,antagonizes gentamycin. Decreased efficacy of flurocytosine.
Purity :Not less than 99%.
Request
Callback
Yes! I am interested

Cytarabine Injection

Cytarabine Injection
  • Cytarabine Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

UsageHospital
Product Type Finished Product

It is an amino pyrimidine. It acts mainly in the S-phase of cell cycle when cell is undergoing DNA synthesis. It acts by inhibition of DNA polymerase

Composition :Each vai l contains:
Cytarabine ----------------100mg ,500mg ,1000mg.
Water for injection ------qs.
Indications :Acute non-lymphocytic leukemia of adult and paediatric patients, acute lymphocytic leukaemia chronic myelogenous leukaemia (Blast - phase), meningeal leukaemia (intra - thecal administrations)
.
Contraindications :In patients with history of hypersensitivity to the drug, pregnancy, location.
Pharmacological action:It is an antineoplastic and immuno modulating agent. It is an amino pyrimidine. It acts mainly in the s-phase of cell cycle when cell is undergoing DNA synthesis. It acts by inhibition of DNA polymerase
Adverse Effects :: Bone marow depression which is dose and schedule dependent, nausea, vomiting, diarrhoea, abdominal pain, oral ulceration, hepatic dysfunction infections, paraplegia and necrotising ieukoencephalopathy occurs after intrathecal administration.
Cytarabine syndrome usually occurs 6-12 hours following drug administration. Its characterized by fever, myalgia, bone pain, maculopapular rash, conjunctivitis and malaise. It is treated with steroids.
Dosage :In induction therepy of: Acute non lymphocytic Leukaemia - 100 mg. / m² / day continuous i.v infusion (days 1-7) or 100 mg./m² i.v every 12 hrs. In meningococcal Leukaemia:
Intrathecal - 5 mg/m²- 75 mg/m² of BSA most frequently used dose in 30 mg/m² every 4 days until CSF findings are negative cytarabine liposome:
Intrathecal - 5 mg/m²- 75 mg/m² of BSA most frequently used dose in 30 mg/m² every 4 days until CSF findings are negative cytarabine liposome
Drug interaction:The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.
Since cyclophosphamide has been reported to be more toxic in adrenalectomized, adjustment of the doses of both replacement steroids and cyclophosphamide may be necessary for the adrenalectomized patient..
Precautions:Special attention to the possible development of toxicity should be exercised in patients being treated with cyclophosphamide if any of the following conditions are present.
• Leukopenia
• Thrombocytopenia
• Tumor cell infiltration of bone marrow
• Previous X-ray therapy
• Previous therapy with other cytotoxic agents
During treatment, the patient's hematologic profile (particularly neutrophils and platelets) should be monitored regularly to determine the degree of hematopoieticsuppression. Urine should also be examined regularly for red cells which may precede hemorrhagic cystitis.
Request
Callback
Yes! I am interested

Irinotecan Injection

Irinotecan Injection
  • Irinotecan Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
TypeAllopathic

Category: Anticancer
Each vial contains:- Irinotecan 40mg/2ml, 100mg/5ml
Specifications :- Irinotecan injection is supplied as a sterile, pale yellow, clear, aqueous solution. The pH of the solution is in between 3.0 to 3.8.

Composition :Each vial contains:
Irinotecan ………………….. 40mg/2ml, 100mg/5ml Water for Injection ……. q.s.
Indications :It is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.
It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
.
Contraindications :It is contraindicated in patients with a known hypersensitivity to the drug or its excipients.
Pharmacological action:Irinotecan is a derivative of camptothecin. It interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks.
Adverse Effects :: Abdominal discomfort, diarrhoea, Leukopenia, neutropenia, haemorrhage, body pain, insomania, dizziness, anaemia vomiting, nausea
Dosage :Irinotecam should be administered as an intravenous infusion over 90 minutes for both the weekly and once-every-3-week dosage schedules.
Weekly dose schedule: The usual starting dose is 125 mg/m2. Subsequent doses may be adjusted to as high as 150 mg/m2.
Once every three week schedule: starting dose is 350 mg.m2
Storage:2-80C
Purity :Not less than 99%.

Request
Callback
Yes! I am interested

Vinblastine Injection

Vinblastine Injection
  • Vinblastine Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
TypeAllopathic

It inhibits micro tubule formation in the mitotic spindle thus arresting cell division in meta phase.
Category:Antineoplastics.
Composition :Each vial contains
Vinblastin Sulphate USP…….. 1.0mg

Indications :Vinblastine sulfate (vinblastine sulfate injection) is indicated in the treatment of the following:
• Frequently Responsive Malignancies
• Generalized Hodgkin's disease
• Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated)
• Histiocytic lymphoma
• Mycosis fungoides (advanced stages)
• Advanced carcinoma of the testis
• Kaposi's sarcoma
• Letterer-Siwe disease
• Less Frequently Responsive Malignancies
• Choriocarcinoma resistant to other chemotherapeutic agents
• Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy

.
Contraindications :Pregnancy. Granulocytopenia, Bacterial infections.

Adverse Effects :Hair loss, leucopenia, neuritic pain, constipation, sensory loss, paresthesias, difficulty in walking (stepping gait), loss of deep tendon reflexes, muscle wasting, fever, hypersensitivity reaction, weight loss, polyuria, urinary retention, hypertension, hypotension, cranial nerve palsy, headache, bone pains, jaw pain, parotid pain, myalgia, convulsions, syndrome of inappropriate secretion of ADH..
Dosage :Given I.V. at weekly intervals. Children : 2mg/m2 (if <10kg, start with 0.005 mg/kg/week) adult : 1.4mg/m2. Decrease the dose to 50%, if S. bilirubin is >3mg/dl. Not given to patients getting radiation therapy through ports that include liver.
Precautions:Toxicity may be enhanced in the presence of hepatic insufficiency.
• Acute uric acid nephropathy,
• Acute shortness of breath
severe broncospasm have been reported following the administration of vinca alkaloids.
Storage2-8°c.

Request
Callback
Yes! I am interested

Dactinomycin Injection

Dactinomycin Injection
  • Dactinomycin Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

UsageCommercial
Form of MedicineInjection

Category: Anti-neoplastic
Each vial contains: Dactinomycin USP 500 mcg
Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA (prevention of RNA polymerase elongation) and, consequently, with protein synthesis.

Specification-pH range- 5.5 to 7.5
Dactinomycin is a clear, gold-colored liquid given into a vein (IV).
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy.
Indication :For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen.
Dosage :-Dose intensity per 2-week cycle for adults or children should not exceed 15 mcg/kg/day or 400-600 mcg/m²/day intravenously for five days.
Contra Indications:-Active infection with chiken pox or herpes zoster (a severe generalized form of disease may occure), infants less than12 months.
Precautions:-This drug is not recommended for use during pregnancy. Precaution is advised when using this drug in the elderly because they may be more sensitive to the effects of the drug, especially the effect on blood cell production (myelosuppression).
Drug interaction:Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Adverse effects:Nausea, vomiting, malaise, fatigue, cheilitis, dysphagia, bone marrow depression gastric ulceration, hepatitis, hepatomegaly, abnormal liver function, alopecia, skin eruotion.
Storage:Powder for injection at room temperature (59° to 86°F). Protect from light and humidity.
Request
Callback
Yes! I am interested

Vincristine Injection

Vincristine Injection
  • Vincristine Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

Form of MedicineInjection
UsageCommercial
TypeAllopathic

Alkaloid extract from a herb-Vinca rosea. Inhibits microtubule formation in the mitotic spindle thus arresting cell division in metaphase.

Composition :1mg/ml,2mg/2ml
Indications :Acute leukemia, lymphomas, Hodgkin's disease, non-Hodgkin lymphosarcoma, neuroblastoma, rhabdomyosarcoma, Wilm's tumour.
Contraindications :Pregnancy, lactation, demyelinating form of Charcot Marie tooth disease.
Safety Profile :The needle should be properly placed in the vein. If leakage occurs in surrounding tissues, considerable irritation will occur. Local injection of hyaluronidase & moderate heat will minimize the discomfort. Used only by iv route. Considerable irritation can occur if extravasated into surrounding tissue.
Adverse Effects :Hair loss, leucopenia, neuritic pain, constipation, sensory loss, paraesthesia, difficulty in walking, loss of deep tendon reflexes, muscle wasting, fever, hypersensitivity reaction, weight loss, polyuria, urinary retention, hypertension, cranial nerve palsies, headache, bone pains, jaw pain, parotid pain, myalgia, convulsions, syndrome of inappropriate secretion of ADH.
Drug Interactions :If given with phenytoin, there is increased seizure activity. Acute bronchospasm with mitomycin-C.
Dosage :Given iv at weekly intervals.
Children : 2mg/m² (if <10kg, start with 0.05mg/kg/week).
Adult : 1.4 mg/m².
Decrease the dose to 50%, if S. bilirubin is >3mg/dl. Not given to patient getting radiation thereby through ports that include liver.
Purity :Not less than 99%.
Request
Callback
Yes! I am interested

Vinorelbine Injection

Vinorelbine Injection
  • Vinorelbine Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

UsageCommercial, Clinical, Hospital
Form of MedicineInjection
Medicine TypeAllopathic
Dosage FormInjection
Grade standardMedicine Grade
Type of MedicinesAllopathic

It is a semi-synthetic vinca alkaloid. It interfere with microtubules, which compose of miotic spindle fibres leading to cell cycle arrest in the metaphase.

Composition :10mg/1ml,20mg/5ml,50mg/5ml
Indications :Non small cell lung carcinoma, breast carcinoma, Hodgkin's disease, ovarian carcinoma, squamous cell carcinoma of the head and neck, cervical, SCLC, renal cell cancer and kaposi's sarcoma.
Contraindications :Hypersensitivity, intrathecal administration as it is extremely irritating.
Safety Profile :Monitor patients with pre-existing neuropathy. Careless causes extravasation.
Adverse Effects :Granulocytopenia, anaemia thrombocytopenia, vomiting, nausea, muscle weakness.
Dosage :Initial dose of 30mg/m² weekly over a period of 6-10 min. No dose adjustment is required for renal insufficiancy.
Purity :Not less than 99%.
Request
Callback
Yes! I am interested
X

Explore more products



Reach Us
Gaurav Chawla (Director)
S. C. O. 162-164, Indian Airlines Building Top Floor
Sector 34-A, Chandigarh -160022,India



Call Us

Share Us

F GT L


Send E-mailSend SMS